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Abstract
Despite the appearance of new treatment, dietary approach remains the mainstay of PKU therapy. The nutritional
management has become complex to optimize PKU patients’ growth, development and diet compliance. This
paper review critically new advances and challenges that have recently focused attention on potential relevant of
LCPUFA supplementation, progress in protein substitutes and new protein sources, large neutral amino acids and
sapropterin. Given the functional effects, DHA is conditionally essential substrates that should be supplied with PKU
diet in infancy but even beyond. An European Commission Programme is going on to establish quantitative DHA
requirements in this population. Improvements in the palatability, presentation, convenience and nutritional
composition of protein substitutes have helped to improve long-term compliance with PKU diet, although it can
be expected for further improvement in this area. Glycomacropeptide, a new protein source, may help to support
dietary compliance of PKU subject but further studies are needed to evaluate this metabolic and nutritional issues.
The PKU diet is difficult to maintain in adolescence and adult life. Treatment with large neutral amino acids or
sapropterin in selected cases can be helpful. However, more studies are necessary to investigate the potential role,
dose, and composition of large neutral amino acids in PKU treatment and to show long-term efficacy and
tolerance. Ideally treatment with sapropterin would lead to acceptable blood Phe control without dietary
treatment but this is uncommon and sapropterin will usually be given in combination with dietary treatment, but
clinical protocol evaluating adjustment of PKU diet and sapropterin dosage are needed.
In conclusion PKU diet and the new existing treatments, that need to be optimized, may be a complete and
combined strategy possibly positive impacting on the psychological, social, and neurocognitive life of PKU patients.
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Introduction
Since the first attempt to treat a patient affected by phe-
nylketonuria (PKU) with a low phenylalanine (Phe) diet,
many steps forward have been made in the treatment of
PKU. Progress in the development of alternative
approaches to the treatment of PKU has been very
impressive over the past decade (large neutral amino
acids, sapropterin and more recently phenilalanine
ammonia lyase or gene therapy). Nevertheless, since
nutritional intervention remains essential in the manage-
ment if this disease, we must be aware of the new
advances and challenges in the nutritional management
of PKU. This paper review critically new advances and
challenges that have recently focused attention on
potential relevant of long chain polyunsaturated fatty
acids (LCPUFA) supplementation, progress in protein
substitutes and new protein sources, large neutral amino
acids, sapropterin and phenilalanine ammonia lyase.
Goals of dietary treatment
The main goals of treatment for PKU is to maintain the
blood Phe levels within safe limits (i.e. ranging 120-360
umol/L, for pregnant women 120-240 umol/L), to pre-
vent mental retardation, to ensure normal growth and
normal life with good health through adulthood. This
can be done by introduction of a low-Phe diet. When
started in the neonatal period it modifies the metabolic
phenotype and prevents the neuropsychological conse-
quences of hyperphenylalaninemia [1]. Indeed it is
known that high blood Phe levels are neurotoxic, mainly
for its inhibitory action on the transport of free L-amino
acids (leucine, isoleucine, valine, tyrosine, tryptophan,* Correspondence: elvira.verduci@unimi.it
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and lysine), necessary for the protein and neurotrans-
mitters synthesis (dopamine and serotonin). The aim of
the dietary treatment is to avoid acute and chronic
increased concentrations of Phe in plasma and conse-
quently in cerebral tissue, responsible for a important
worsening of the neuronal performance and the beha-
viour [1]. Prognosis and outcome strongly depend on
the age when the diagnosis is made and treatment intro-
duced, but also on the type of mutation. Because of evi-
dence that early ending of treatment might impair later
neuropsychological performance, the treatment of PKU
is recommended for life [1]. Compliance with treatment
is adequate in infancy and childhood, however difficul-
ties in maintaining a PKU diet in adolescent and adult-
hood are reported [2]. Based on a survey of 10
European centres, Ahring et al. [3] concluded that on
average only in 65% of samples from patients above 16
years of age Phe values were within or below guideline
goals.
Although elevated Phe concentrations seem to have
smaller influence on brain functioning beyond early
childhood [4], there is evidence that numbers of neurop-
sychological and neurophysiological dysfunctions can
appear in older patients, as the consequence of losing
metabolic control [2] and that may be associated to sub-
sequent poor school and work performance [2].
Although severe neurological damage is completely pre-
vented in PKU affected individuals by adequate dietary
therapy, subtle neurological deficits persist and are
detectable. For example, the IQ of well and early treated
PKU children participating in the German Collaborative
Study was 3-6 points lower than that of their healthy
siblings [5]. Moreover in this study was observed that
after early and strict treatment during the preschool
years, variation of observed Phe did not influence IQ
development at school age. Thus, other factors than the
degree of Phe control appear to influence cognitive out-
comes. In another study, early and continuously treated
PKU patients of ages 8 to 20 years were compared with
controls with respect to behaviour and school achieve-
ments [6]. PKU patients demonstrated more problems
in task-oriented behaviour and average academic perfor-
mance than controls.
PKU diet: nutritional characteristics
The restriction of dietary phenylalanine remains the
mainstay of PKU management and usually begins imme-
diately after confirmation of this condition in a new-
born. Patients with PKU have to avoid foods rich in
protein (meat, fish, eggs, standard bread, dairy products,
nuts, and seeds) and foods and drinks containing aspar-
tame, flour, soya, beer, or cream liqueurs. Therefore
PKU diet is mainly made up by low-protein natural
foods (vegetables, fruits and some cereals), poor in Phe,
to reach the Phe supply necessary for growth processes.
Low-protein variants of some foods are commercially
present, such as low-protein bread and low-protein
pasta. The quantities of the permitted natural foods are
calculated from a method of Phe equivalence (depen-
dent upon how much Phe a food contains for a given
weight). The required amount of daily protein is
obtained from Phe-free protein substitutes providing
essential amino acids in suitable proportions.
During infancy breastfeeding or human milk meals [7],
to provide natural protein according to the individual
Phe tolerance, and a Phe-free infant formula are
recommended.
This type of dietary regimen, provide lower saturated
and polyunsaturated fat, cholesterol, carnitine taurine,
iron, zinc, selenium, calcium, folates, A, C, D, E and B2,
B6, B12 vitamins intake, because of the very low
assumption of Phe-containing animal foods, as well as
higher carbohydrates intake than healthy pediatric popu-
lation. Therefore there is a general agreement that
patients with PKU need long-term dietary counseling
and daily micronutrients supplementation. However
some advantages of this dietary treatment should be
considered. The PKU diet follows the norms of the so-
called “prudent” diet for the prevention of cardiovascu-
lar disorders. In particular saturated fats may be less
than 7% and polyunsaturated higher than 5% total
energy with a supply less than 50 mg cholesterol per
day [8]. Indeed PKU children show lower plasma choles-
terol levels as compared to healthy children, particularly
low density lipoprotein particles [9]. Nevertheless both
dietary habits and genetic predisposition (apo B and apo
E polymorphisms) may interact in keeping low blood
lipid levels in PKU population [9].
PKU: nutritional advances and challenges
PKU and LCPUFA
Rationale for LCPUFA supplementation PKU children
who are compliant with the recommended low protein
diet are devoid of natural dietary sources of n-3
LCPUFA, as LCPUFA rich foods also contain high
amounts of protein. Accordingly, blood concentrations
of n-3 LCPUFA and especially of docosahexaenoic acid
(DHA) are reduced in plasma and red blood cell phos-
pholipids of PKU children relative to omnivorous chil-
dren [10-12] with a more marked relative depletion of
DHA than arachidonic acid, the major n-6 LCPUFA,
throughout childhood. LCPUFA with 20 and 22 carbon
atoms are metabolically derived from a-linolenic acid
(ALA) and linoleic acid (LA) by consecutive enzymatic
desaturation and chain elongation. Although LCPUFA
including DHA (22:6n-3) and AA (20:4n-6) can be
synthesized from ALA and LA in mammals, respectively,
the activity of conversion is low in humans particularly
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for the synthesis of DHA, which is formed through a far
more complex and indirect metabolic pathway than AA
[13]. Blood levels of AA are influenced by polymorph-
isms of the fatty acid desaturase genes to a far greater
degree than DHA levels (around 28-30% vs 2-3%) [14],
which also points towards a low contribution of endo-
genous n-3 conversion to DHA and the importance of a
preformed dietary intake of DHA. There is increasing
awareness of the importance of DHA for optimal neuro-
logical function in humans. DHA status during prenatal
and postnatal development has been linked to benefits
for child outcomes in several studies [15]. In particular
the striking variations that have been found in the DHA
content of prefrontal brain cortex in breastfed compared
with formula-fed infants provide convincing evidence of
the effects of a dietary supply of LCPUFA on the struc-
ture of the brain [16]. The extremely low dietary DHA
intake in PKU children, with resulting low blood and
presumably tissue DHA contents, may have adverse
consequences for central nervous function, which might
contribute to learning difficulties, behavioral abnormal-
ities and visual problems found in PKU patients [17-19].
Early dietary treatment of PKU prevents severe neurolo-
gical damage and generally leads to normal cognitive
development, but subtle neurological deficits persist [5].
Poorer school performance of PKU children was
reported, with significantly lower academic performance,
initiative and progress than in age matched omnivorous
children [6]. These subtle functional deficits in early and
well treated individuals with PKU are not explained by
variations in plasma Phe levels, and it is plausible that a
low DHA supply induced by the extremely restricted
diet contributes to neurological abnormalities.
LCPUFA supplementation: infancy and childhood
Because the first few months of life represent the most
vulnerable period for brain development, early supple-
mentation with preformed LCPUFA could be an impor-
tant addition to the nutrition of infants with PKU [15].
A double-blind randomized trial [20] showed that a
dietary supply of LCPUFA in infants with PKU (a Phe-
free formula supplemented with DHA, 0.3 g/100 g fatty
acids, and AA, 0.7 g/100 g) prevents the decline in
DHA status associated with a diet supplying minimal
sources of LCPUFA (breast milk).
Therefore by using a phenylalanine-free infant formula
supplemented with LCPUFA in the first year of life, the
risk that infants with PKU will have sub-optimal DHA
status may be minimized.
Hovewer, LCPUFA supplementation is not routinely
provided in PKU after infancy. In PKU children one
double-blind, placebo-controlled randomised trial was
conducted to elucidate the biochemical and functional
effects of LCPUFA supplementation [21]. Twenty chil-
dren with PKU received supplementation either with a
fat blend balanced in both n-3 and n-6 LCPUFA (pro-
viding about 8 mg eicosapentaenoic acid, EPA, and 10
mg DHA per Kg body weight per day) or placebo for 12
months (olive oil). Both n-3 and n-6 fatty acids were
supplemented to avoid biochemical imbalances. By the
end of the trial plasma levels of these fatty acids raised
and the latency time in the P100 wave of visually evoked
potentials (VEP) decreased significantly in children
receiving the preparation with LCPUFA. However, 3
years after supplementation, no biochemical or func-
tional differences between supplemented and unsupple-
mented children were apparent [22]. In 2 open clinical
trials [23,24], also including a few children younger than
2 years, a 3 month supplementation of patients with
classical PKU with fish oil providing EPA and DHA (15
mg of DHA per kg of body weight per day) without
major amount of n-6 LCPUFA, significantly increased
n-3 LCPUFA levels in plasma phospholipids, but also
significantly decreased the arachidonic acid level, and
shorted the latencies of VEP and improved the perfor-
mance in the Rostock-Oseretzky Scale for coordination
and fine motor skills [24].
In conclusion given the functional effects, DHA is
conditionally essential substrates that should be supplied
with PKU diet even beyond infancy. Their addition to
the synthetic amino acid mixtures appears advisable.
LCPUFA supplementation: dosage The dosage used in
Beblo study [24] resulted in supra-normal plasma n-3
LCPUFA and reduced AA levels, hence the daily dose of
15 mg DHA/Kg may be higher than the dose needed for
oprimal outcomes. In addition to a required confirma-
tion of the observed DHA effects in a further study,
quantitative needs should be established [25]. With
financial support provided by the 7th Framework
Research Programme of the European Commission, a
multicentre randomized clinical trial in school age PKU
children is currently going on (NUTRIMENTHE EU
Project “Effect of Diet on Mental Performance of Chil-
dren” FP7-KBBE-2007-1, GA: 212652). PKU children,
school age, will be randomised to receive different
dosage of DHA supplement (0-15 mg/Kg/day) and will
be tested for functional outcomes both before and after
supplementation [25]. This trial may achieve to establish
quantitative DHA requirements in children and thus
may allow conclusions on the desirable dietary DHA
supply to healthy children, since there are no indications
that PKU-children have any alterations of energy and
fatty acid metabolism, and of DHA absorption, distribu-
tion, metabolism and excretion.
LCPUFA supplementation: other paediatric and
adult PKU related population Pregnant women with
PKU and poorly compliant patients with the condition
also might benefit from preformed LCPUFA supplemen-
tation. Supplementation of pregnant women should help
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assure maximal placental transfer of these fatty acids
during the last 3 months of pregnancy. According to
international recommendations, healthy pregnant
woman should consume preformed n-3 LCPUFA pro-
viding an average intake of at least 200 mg DHA/day on
a regular basis [15]. Moreover supplementation of
poorly compliant patients should provide higher levels
of neuroprotection and lessen the theoretical risk of
inhibition of endogenous LCPUFA synthesis by toxic
phenylalanine by-products. In fact, it has been observed
that [17], in the patients with inadequate metabolic con-
trol, the increased concentrations of Phe and of its
metabolites, phenylpiruvic and fenyllactic acids, can
inhibit for competition the synthesis of an important
enzymatic cofactor, the a-tocopherolchinone, which
facilitates the action of the desaturase in the synthesis
process of fatty acids.
Studies are needed to evaluate the optimal dosage of
DHA supplementation in PKU pregnancy and in PKU
poorly compliant patients.
Progress in the dietary treatment: protein substitutes and
new protein sources
Protein substitutes The number of protein substitutes
(mixtures of amino acids that are free from or low in
Phe) available for PKU patients is increasing constantly
with time [26]. The absence of Phe is the one constant
in these mixtures; there is variability in the presence or
absence of lipids, vitamins and minerals with differences
also in the amount.
The major progresses in protein substitutes are:
⇒ Palatability and caloric content: better taste of
amino acid powder/lower calories (lipid and carbo-
hydrate composition of preparations have been
improved);
⇒ Compliance (all ages): better compliance due to
different formulations (powder, tablets, shake,
creams etc)
⇒ Age-related problems with diet (childbearing age,
adolescence, adult age,): different age-related formu-
las and composition ® individualized dietary
treatment.
Improvements in the palatability, presentation, conve-
nience and nutritional composition of substitutes have
helped to improve long-term compliance with PKU diet,
although it can be expected for further improvement in
this area. About the composition of the mixtures
according the different age we could consider:
1) Phe-free mixtures of amino acids for infants 0-12
month: the composition of each products meets
infants’ requirements. Most of the different protein
substitutes contain DHA and AA and some formula-
tions are supplemented with prebiotics.
2) Phe-free mixtures of amino acids for children,
adolescents and adults: many products are available
with different composition and presentation. This
represents a great advantage for patients as they can
choose the product most likely to meet their needs.
Nevertheless the use of protein substitutes should
continue to be observed and monitored the efficacy pro-
ven in long-term studies.
New protein sources: glycomacropeptide Glycomacro-
peptide (GMP) is a protein derived from cheese whey
that is rich in specific essential aminoacids but it is the
only known natural protein that in its purified form is
free of tyrosine, tryptophan and phenylalanine (aromatic
aminoacids) and therefore could provide an alternative
protein source for PKU individuals when manufactured
to sufficient purity to ensure it is free from Phe that
could be contained in traces of other whey proteins and
with supplementation of missing aromatic amino acids
other than Phe [27]. In the last years progresses in eval-
uating the safety, acceptability and efficacy of GMP in
the nutritional management of PKU have been per-
formed [28]. A variety of foods and beverages can be
made with GMP to improve the taste, variety and con-
venience of the PKU diet. Sensory studies in individuals
with PKU demonstrate that GMP foods are acceptable
alternatives to amino acid medical foods. Studies in the
PKU mouse model demonstrate that GMP supplemen-
ted with limiting indispensable amino acids (tyrosine
and tryptophan) provides a nutritionally adequate source
of protein and improves the metabolic phenotype by
reducing concentrations of Phe in plasma and brain
[29]. In a recent study on 11 PKU patients the GMP
diet was preferred to the amino acid diet [30]. When
comparing fasting with postprandial plasma, plasma Phe
concentration increased significantly with the amino
acid diet but not with the GMP diet. Blood urea nitro-
gen was significantly lower, which suggests decreased
urea genesis, and plasma insulin was higher with the
GMP diet than with the amino acid diet. The authors
concluded that GMP, when supplemented with limiting
amino acids, is a safe and highly acceptable and may
improves protein retention and Phe utilization com-
pared with amino acid diet. A more recent study assess
the ability of a GMP breakfast to promote satiety in 11
PKU subjects (8 adults and 3 boys ages 11-14), when
compared to an amino acid-based breakfast [31]. Post-
prandial ghrelin concentration was significantly lower
with GMP, associated with greater feelings of fullness
after breakfast, compared to an amino acid-based break-
fast, with no difference in fasting ghrelin. Postprandial
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concentrations of insulin and total plasma amino acids
were higher after a GMP breakfast compared to an
amino acids-based breakfast consistent with slower
absorption and less degradation of amino acids from
GMP.
In conclusion GMP may help to support dietary com-
pliance of PKU subject but further studies are needed to
evaluate this metabolic and nutritional issues.
New strategies
The PKU diet is difficult to maintain in adolescence and
adult life. Many adults discontinue it or refuse to return
to it, which is a continuous challenge in the follow-up
of PKU. Treatment with large neutral aminoacid
(LNAA) supplements or tetrahydrobiopterin (BH4)
cofactor in could be helpful.
Large neutral amino acids Apart from Phe, LNAAs
include tyrosine, tryptophan, threonine, methionine,
valine, isoleucine, leucine, and histidine. In healthy indi-
viduals, all of these except tyrosine are essential amino
acids. In patients with PKU, tyrosine has become an
essential amino acid. LNAA treatment as an alternative
to dietary Phe restriction was suggested as early as 1953
[32]. Since then, different combinations of LNAAs have
been designed, based on different rationales and treat-
ment targets. Recently the use of LNAAs as an alterna-
tive treatment in PKU have been reviewed [33]. LNAAs
supplementation may have multiple treatment targets: a
specific reduction in brain phenylalanine concentrations,
a reduction in blood (and consequently brain) phenyla-
lanine concentrations, an increase in brain neurotrans-
mitter concentrations, and an increase in brain essential
amino acid concentrations. Although LNAA treatment
in PKU was initially intended to be unrestricted natural
protein intake combined with LNAA supplementation,
it should be noted that not all authors studied LNAA
supplementation in this manner. Pietz et al. [34] con-
firmed that the LNAA blocked the Phe transport into
the brain by giving an oral ‘’Phe challenge’’ with and
without LNAA and measuring the influx of Phe into the
brain. The use of the LNAA therapy has been shown to
improve amino acid profiles as well as increase tyrosine
and tryptophan concentrations in the blood, which are
precursors for dopamine and serotonin [35]. A short-
term double-blind placebo control study, using LNAA
in patients with PKU, showed a lowering of blood Phe
concentration by an average of 39% from baseline [36].
Additionally LNAA treatment seems to have a beneficial
effects on executive functioning [37].
In conclusion, LNAA treatment is seen as an alterna-
tive to conventional dietary PKU treatment. LNAA
treatment may refer to at least two different LNAA
treatment strategies, i.e., natural protein intake at
Recommended Dietary Allowance (RDA) with LNAA
supplementation, and conventional dietary therapy
combined with LNAA supplementation. In addition,
LNAA treatment may refer to supplementation of single
amino acids, such as tyrosine, tryptophan, and threo-
nine. These differences in treatment strategies are based
on clearly different theories regarding mechanism of
action. Consequently, more studies are necessary to
investigate the potential role, dose, and composition of
LNAA in PKU treatment and to show long-term efficacy
and tolerance.
Sapropterin dihydrochloride supplementation in BH4
responsive PKU patients Long-term adherence (and
hence metabolic control) to PKU diet is commonly
poor. Some phenylalanine hydroxylase (PAH) mutations
are associated with a BH4-sensitive phenotype of PKU,
in which giving pharmacological doses of exogenous
BH4 results in an increase in the activity of PAH [38].
These mutations usually present with substantial resi-
dual activity. Indeed response to BH4 is usually more
pronounced in mild or moderate PKU. Patients with
PKU (usually, but not exclusively, with a relatively mild
form of the disorder) who are responsive to treatment
with pharmacological doses of BH4 have either lower
concentrations of blood phenylalanine or improved diet-
ary phenylalanine tolerance [2,39]. The availability of a
registered formulation of BH4 (sapropterin dihy-
drochloride) has raised many practical issues and new
questions in the dietary management of these patients
[40]. Approssimately 20-60% of patients have been sho-
wen to achieve a > 30% reduction in blood Phe levels
with sapropterin or previous unregistered formulation of
BH4 [40]. Ideally treatment with sapropterin would lead
to acceptable blood Phe control without dietary treat-
ment but this is uncommon and sapropterin will usually
be given in combination with dietary treatment.
Sapropterin and PKU diet Initially, patients and carers
must understand clearly the likely benefits (and limita-
tions) of sapropterin therapy. A minority of patients
who respond to sapropterin are able to discontinue the
phenylalanine-restricted diet completely, while others
are able to relax the diet to some extent. Care is
required when altering the phenylalanine-restricted diet,
as this may have unintended nutritional consequences
and must be undertaken with caution. New clinical pro-
tocols are required for managing any dietary change
while maintaining control of blood phenylalanine, ensur-
ing adequate nutrition and preventing nutritional defi-
ciencies, overweight or obesity. An accurate initial
evaluation of pre-sapropterin phenylalanine tolerance is
essential, and the desired outcome from treatment with
sapropterin (e.g. reduction in blood Phe or relaxation in
diet) must also be understood by the patient and carers
from the outset. Continuing education and support will
be required thereafter, with further adjustment of diet
and sapropterin dosage as a young patient grows.
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Multicentric standardised long-term studies are neces-
sary to assess the nutritional adequacy, growth, body
composition, blood Phe control during illness, diurnal
blood Phe variability and changes in the quality and
variety of foods eaten. Guidance is needed about the
amount and type of natural protein that should be con-
sumed before protein substitute is stopped and how
best to introduce dietary Phe with sapropterin. In addi-
tion only data for the effect on Phe metabolism are
available. Data for neurocognitive outcomes in these
patients are scarce [41] and little is known about
longer-term adherence to sapropterin treatment. New
protocols are required for managing dietary treatment
in association to use of sapropterin.
Phenylalanine ammonia lyase Phenylalanine ammonia
lyase (PAL) is a plant-derived enzyme that also degrades
phenylalanine (without synthesizing tyrosine), but it is
more stable than PAH and does not require a cofactor.
Pegylated PAL (PEG-PAL) is a novel formulation of
PAL that is currently undergoing clinical trials. Recently
in a mouse model of phenylketonuria [42], the PEG-
PAL, given orally, showed promising results with a
mean blood phenylalanine level reduction of around
40% and no serious adverse reactions. Phe reduction
occurred in a dose- and loading-dependent manner. In
conclusion oral PAL therapy could be an adjunct ther-
apy, perhaps with dietary treatment, independently from
the PAH genotype.
Conclusion
In PKU severe neurological and functional disorders can
be prevented through an early strict nutritional treat-
ment aimed at reducing blood Phe to non-toxic levels
through a PKU diet. The outcome for patients with
PKU treated from the first weeks of life is generally
excellent with children attaining developmental mile-
stones and attending normal schools. Significant clinical
psychological and neurocognitive abnormalities are
observed in patients non-compliant with PKU.
New advances and challenges has been performed in
the nutritional management of PKU (i.e. LCPUFA sup-
plementation, progress in protein substitutes and new
protein sources). Long term dietary guidance and moni-
toring of the nutritional status of patients with PKU
should be part of a follow-up programme that continues
for life. Pediatricians and dieticians should prescribe and
carefully monitor macronutrient and micronutrient
intake, growth and physical activity in PKU patients.
New treatments exist-such as LNAA and sapropterin -,
that need to be optimized as far as targets, expected
outcomes and nutritional follow up. In particular a clini-
cal protocol evaluating adjustment of PKU diet and
sapropterin dosage are needed. Therefore despite the
appearance of new advances and strategies, dietary
treatment remains the mainstay of PKU therapy. More-
over the new treatment options (LNAA, sapropterin,
PAL) for the management of PKU are expanding, and
do not always allow a complete relaxation of PKU diet.
Therefore the nutritional treatment is always essential.
However it is necessary evaluate if PKU diet and the
new treatment options in combination may really matter
in the psychological, social, and neurocognitive life of
PKU patients. Anyway a complete strategy should
include anyway long term dietary guidance and moni-
toring of the nutritional status of PKU patients.
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